On January 4, 2022 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, reported that Brian M. Culley, Chief Executive Officer will be presenting at the H.C. Wainwright Bioconnect Virtual Conference (Press release, Lineage Cell Therapeutics, JAN 4, 2022, View Source [SID1234598084]). The corporate presentation will be available to investors on demand, starting on January 10, 2022 at 7:00am ET on the Events and Presentations section of Lineage’s website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!